Meta Data Description/Summary: Baylor Scott & White Health and Select Medical announce an expansion of their long-standing joint venture with the operation of a 45 bed inpatient rehabilitation hospital in Temple.
The hospital, located at 725 Marlandwood
...
Baylor Scott & White Health, the largest not-for-profit health system in Texas, announces a new partnership with Surgery Partners, Inc. to jointly own with physicians the 16-bed hospital in Bryan known as The Physicians Centre Hospital.
Levanto — developed by Baylor Scott & White Health and offering tech-enabled healthcare solutions to employers, payors and health systems — has named Kevin Kumler as president and general manager.
Baylor Scott & White Health, the largest not-for-profit health system in Texas, announces new patient care sites and expanded digital care offerings to meet the rapidly growing healthcare needs of North and Central Texas. The new locations will offer more
...
A new joint venture is aimed at increasing access to high-quality outpatient mental health services for Texans. The partnership is built around the idea that care should meet people where they are — whether that’s in person or online — by creating more wa
...
A breast cancer research study now open at Baylor University Medical Center in Dallas is believed to be the first of its kind to explore the ability of new weight loss GIP/GLP-1 receptor agonists to combat breast cancer recurrence in overweight or obese pa
...
In 2023, Baylor Scott & White Quality Alliance, the largest clinically integrated network in Texas, significantly exceeded average performance for nearly all quality measures tracked by the Medicare Shared Savings Program (MSSP) and remains a top performer
...
The US Army Medical Research and Development Command, a division of the Department of Defense, awarded a $2.7 million grant to Dr. Ann Marie Warren, PhD, ABPP, principal investigator for Baylor Scott & White Research Institute, to research prevent Post-tra
...
The study results show exciting immune responses in patients with operable esophageal or gastroesophageal cancers given neoadjuvant immunotherapy and highlight the potential for monitoring circulating tumor DNA as a predictor for future intervention.
